Clinical Trial Update: Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib [Phase 4]

View source ↗

Summary

Phase 4 trial results update on using nilotinib as first-line therapy for metastatic or unresectable gastrointestinal stromal tumors (GIST); results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 4 | Status: COMPLETED | Results posted: 2026-01-20